Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis by Fox, Robert J, Coffey, Christopher S, Cudkowicz, Merit E, Gleason, Trevis, Goodman, Andrew, Klawiter, Eric C, Matsuda, Kazuko, McGovern, Michelle, Conwit, Robin, Naismyth, Robert, Ashokkumar, Akshata, Bermel, Robert, Ecklund, Dixie, Koepp, Maxine, Long, Jeffrey, Natarajan, Sneha, Ramachandran, Srividya, Skaramagas, Thomai, Thornell, Brenda, Yankey, Jon, Agius, Mark, Bashir, Khurram, Cohen, Bruce, Coyle, Patricia, Delgado, Silvia, Dewitt, Dana, Flores, Angela, Giesser, Barbara, Goldman, Myla, Jubelt, Burk, Lava, Neil, Lynch, Sharon, Miravalle, Augusto, Moses, Harold, Ontaneda, Daniel, Perumal, Jai, Racke, Michael, Repovic, Pavle, Riley, Claire, Severson, Christopher, Shinnar, Shlomo, Suski, Valerie, Weinstock-Gutman, Bianca, Yadav, Vijayshree, Zabeti, Aram

Get full text